|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"meyer t"
Showing items 1-25 of 25 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
|
Ren, Z.;Ducreux, M.;Abou-Alfa, G.K.;Merle, P.;Fang, W.;Edeline, J.;Li, Z.;Wu, L.;Assenat, E.;Hu, S.;Rimassa, L.;Zhang, T.;Blanc, J.-F.;Pan, H.;Ross, P.;Yen, C.-J.;Tran, A.;Shao, G.;Bouattour, M.;Chen, Y.;Meyer, T.;Hou, J.;Tougeron, D.;Bai, Y.;Hou, M.-M.;Meng, Z.;Wu, J.;Li, V.;Chica-Duque, S.;Cheng, A.-L. |
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2022-06-10T06:10:51Z |
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
|
Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN; Youkstetter J.; Hazra S.; Sen S.; Cheng A.-L.; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
|
Meyer T.; Palmer D.H.; ANN-LII CHENG; Hocke J.; Loemb? A.-B.; Yen C.-J. |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
|
Abou-Alfa G.K.; Meyer T.; ANN-LII CHENG; El-Khoueiry A.B.; Rimassa L.; Ryoo B.-Y.; Cicin I.; Merle P.; Chen Y.; Park J.-W.; Blanc J.-F.; Bolondi L.; Kl?mpen H.-J.; Chan S.L.; Zagonel V.; Pressiani T.; Ryu M.-H.; Venook A.P.; Hessel C.; Borgman-Hagey A.E.; Schwab G.; Kelley R.K. |
| 臺大學術典藏 |
2021-08-31T06:29:16Z |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
|
Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-31T06:29:14Z |
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
|
Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG; El-Khoueiry A.B.; Abou-Alfa G.K. |
| 臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2021-05-13T03:03:47Z |
External push and internal pull forces recruit curvature-sensing N-BAR domain proteins to the plasma membrane
|
Galic M.; Jeong S.; FENG-CHIAO TSAI; Joubert L.-M.; Wu Y.I.; Hahn K.M.; Cui Y.; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:47Z |
Ca2+ pulses control local cycles of lamellipodia retraction and adhesion along the front of migrating cells
|
FENG-CHIAO TSAI; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:46Z |
XThe proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit
|
Spencer S.L.; Cappell S.D.; FENG-CHIAO TSAI; Overton K.W.; Wang C.L.; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:46Z |
Brg1 governs distinct pathways to direct multiple aspects of mammalian neural crest cell development
|
Li W.; Xiong Y.; Shang C.; Twu K.Y.; Hang C.T.; Yang J.; Han P.; Lin C.-Y.; Lin C.-J.; FENG-CHIAO TSAI; Stankunas K.; Meyer T.; Bernstein D.; Pan M.; Chang C.-P. |
| 臺大學術典藏 |
2021-05-13T03:03:46Z |
A localized Wnt signal orients asymmetric stem cell division in vitro
|
Habib S.J.; Chen B.-C.; FENG-CHIAO TSAI; Anastassiadis K.; Meyer T.; Betzig E.; Nusse R. |
| 臺大學術典藏 |
2021-05-13T03:03:45Z |
Dosage of Dyrk1a shifts cells within a p21-Cyclin D1 signaling map to control the decision to enter the cell cycle
|
Chen J.-Y.; Lin J.-R.; FENG-CHIAO TSAI; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:45Z |
Dynamic recruitment of the curvature-sensitive protein ArhGAP44 to nanoscale membrane deformations limits exploratory filopodia initiation in neurons
|
Galic M.; FENG-CHIAO TSAI; Collins S.R.; Matis M.; Bandara S.; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:45Z |
Neuropilin-2 contributes to tumorigenicity in a mouse model of Hedgehog pathway medulloblastoma
|
Hayden Gephart M.G.; Su Y.S.; Bandara S.; FENG-CHIAO TSAI; Hong J.; Conley N.; Rayburn H.; Milenkovic L.; Meyer T.; Scott M.P. |
| 臺大學術典藏 |
2021-05-13T03:03:44Z |
Engulfed cadherin fingers are polarized junctional structures between collectively migrating endothelial cells
|
Hayer A.; Shao L.; Chung M.; Joubert L.-M.; Yang H.W.; FENG-CHIAO TSAI; Bisaria A.; Betzig E.; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:44Z |
A polarized Ca2+, diacylglycerol and STIM1 signalling system regulates directed cell migration
|
FENG-CHIAO TSAI; Seki A.; Yang H.W.; Hayer A.; Carrasco S.; Malmersj? S.; Meyer T. |
| 國立成功大學 |
2021 |
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study
|
Harding, J.J.;Yang, T.-S.;Chen, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Ho, C.-L.;Huang, W.-T.;El, Dika I.;Akce, M.;Tan, B.;Cohen, S.A.;Meyer, T.;Sarker, D.;Lee, D.-W.;Ryoo, B.-Y.;Lim, H.Y.;Johnston, A.;Bomalaski, J.S.;O’Reilly, E.M.;Qin, S.;Abou-Alfa, G.K. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 國家衛生研究院 |
2018-04-05 |
ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G;Qin, S;Ryoo, BY;Lu, SN;Yen, CJ;Feng, YH;Lim, HY;Izzo, F;Colombo, M;Sarker, D;Bolondi, L;Vaccaro, G;Harris, WP;Chen, Z;Hubner, RA;Meyer, T;Sun, W;Harding, JJ;Hollywood, EM;Ma, J;Wan, PJ;Ly, M;Bomalaski, J;Johnston, A;Lin, CC;Chao, Y;Chen, LT |
| 國立成功大學 |
2018 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.;Qin, S.;Ryoo, B.-Y.;Lu, S.-N.;Yen, C.-J.;Feng, Y.-H.;Lim, H.Y.;Izzo, F.;Colombo, M.;Sarker, D.;Bolondi, L.;Vaccaro, G.;Harris, W.P.;Chen, Z.;Hubner, R.A.;Meyer, T.;Sun, W.;Harding, J.J.;Hollywood, E.M.;Ma, J.;Wan, P.J.;Ly, M.;Bomalaski, J.;Johnston, A.;Lin, C.-C.;Chao, Y.;Chen, L.-T. |
| 國家衛生研究院 |
2016-05 |
Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, GK;Qin, SK;Ryoo, BY;Lu, SN;Yen, CJ;Feng, YH;Lim, HY;Izzo, F;Colombo, M;Sarker, D;Bolondi, L;Vaccaro, GM;Harris, WP;Chen, ZD;Hubner, R;Meyer, T;Bomalaski, JS;Lin, CC;Chao, Y;Chen, LT |
| 國立臺灣大學 |
2016 |
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
|
Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Meyer, T.; Welling, T. H., III; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A.; 許駿 |
| 國立成功大學 |
2015-06-01 |
Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
|
Palmer, D.; Meyer, T.; Chao, Y.; Deptala, A.; Fartoux, L.; Feng, Y. -H.; Graham, J.; Lin, D. -Y.; Ma, Y. T.; Peck-Radosavljevic, M.; Ross, P.; Ryoo, B. -Y.; Yen, C. -J.; Hocke, J.; Vlassak, S.; Wenz, A.; Loembe, A. -B.; Cheng, A. -L. |
Showing items 1-25 of 25 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
